GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

The latest increase reflects the revival of the once-withdrawn antibody-drug conjugate Blenrep, as well as “multiple launch opportunities in the ’26-to-’31 period,” GSK CEO Emma Walmsley ...

GlaxoSmithKline "deliberately" discontinued a widely-used asthma medication in order to reap profits and families suffered, ...

Drug developer GSK is vacating its 635,000-square-foot life sciences lab in Rockville, Maryland, where it was the sole tenant ...

GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs ...

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.

CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit grew 13%, supporting a ...

GSK, a British drugmaker, recently beat Q4 earnings estimates. The company is our FDI of the Month January 2025.